They said it at DeviceTalks Boston

Proximie CEO Nadine Hachach-Haram [Photo courtesy of Proximie]Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead.

Here are some of the most quotable insights from panelists and speakers at our live event.

And make sure to save the date — and save your seat — for DeviceTalks West in Santa Clara, California on Oct. 19 and 20.

Get the full story at our sister site, Medical Design & Outsourcing.

Read more
  • 0

They said it at DeviceTalks Boston

Proximie CEO Nadine Hachach-Haram [Photo courtesy of Proximie]

Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead.

Here are some of the most quotable insights from panelists and speakers at our live event.

And make sure to save the date — and save your seat — for DeviceTalks West in Santa Clara, California on Oct. 19 and 20.

Read on to hear what medtech leaders had to say at DeviceTalks Boston 2022.

Next >>

Read more
  • 0

The biggest stories from the American Diabetes Association (ADA) 2022 Scientific Sessions

For the 82nd time, the American Diabetes Association (ADA) Scientific Sessions convened to highlight all the innovations within the diabetes technology space.

Major players like Dexcom, Medtronic, Abbott and more continue to plug along, while companies like Bigfoot Biomedical, One Drop and others shared data backing the technology that they bring to the table.

The data showcased at ADA supported the usual continuous glucose monitoring (CGM) and automated insulin delivery (AID) technology, plus different digital health platforms and diabetes reversal procedures.

BTIG analyst Marie Thibault wrote in a report that there was plenty of buzz on the ground at the event, particularly around Insulet’s Omnipod 5 AID system, Abbott’s recently FDA-cleared FreeStyle Libre 3 CGM and Bigfoot Biomedical’s Bigfoot Unity platform.

“In general, we believe that accuracy and clinical benefit is proven for all commercial CGM and AID offerings an…

Read more
  • 0

Insulet’s Omnipod 5 “significantly improves” glycemic outcomes in very young children

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]Insulet (Nasdaq:PODD) announced data supporting the use of its Omnipod 5 automated insulin delivery system in young children.

Acton, Massachusetts-based Insulet’s Omnipod 5, which became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. earlier this year, significantly improved time in range and reduced HbA1c in children aged 2 through 5.9 years old with type 1 diabetes over 12 months of use.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet breaks ground on $200M manufacturing facility in Malaysia

[Image from Insulet]Insulet (Nasdaq:PODD) announced the groundbreaking of its new Omnipod manufacturing facility in Malaysia.

Acton, Massachusetts-based Insulet’s Johor Bahru, Malaysia-based manufacturing facility will produce its Omnipod automated insulin delivery system and strengthen the company’s global manufacturing capabilities.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet breaks ground on $200M manufacturing facility in Malaysia

[Image from Insulet]Insulet (Nasdaq:PODD) announced the groundbreaking of its new Omnipod manufacturing facility in Malaysia.

Acton, Massachusetts-based Insulet’s Johor Bahru, Malaysia-based manufacturing facility will produce its Omnipod automated insulin delivery system and strengthen the company’s global manufacturing capabilities.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Dexcom quashes talk of Insulet merger, says discussions are not ongoing

Dexcom (Nasdaq:DXCM) has today issued a statement denying recent rumors of a potential merger with Insulet (Nasdaq:PODD).

Last week, reports circulated saying talks over a potential acquisition were ongoing with an agreement between the two diabetes technology developers on the horizon in the coming weeks.

On the back of the Dexcom statement, DXCM shares were up 7% at $308.87 per share as the market opened today. Conversely, PODD shares sank 11% to $209.65.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Report: Dexcom in talks to acquire Insulet

Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD).

Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg’s sources preferred to remain anonymous because the information is private and both companies declined to offer comment, the news outlet said.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change

The future for Insulet (Nasdaq:PODD) has a much different look on some level than it did about a week ago.

A massive shake-up at the executive level came on May 5 when Shacey Petrovic announced that she would step down as the company’s president and CEO for personal reasons.

Petrovic will stay on as a board member at the Acton, Massachusetts-based automated insulin delivery system developer, and will assume an advisory role to support the leadership transition to former ResMed President of Sleep and Respiratory Care Jim Hollingshead, who will succeed her.

While the executive makeup will change come June 1, Insulet’s efforts to innovate in the diabetes space won’t be halted, as the company will continue to plug along under new leadership, EVP of Innovation and Strategy Eric Benjamin said during a keynote event at DeviceTalks Boston.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Shacey Petrovic to step down as Insulet CEO, ResMed exec Jim Hollingshead to take role

Insulet (Nasdaq:PODD) announced today that President and CEO Shacey Petrovic will step down for personal family reasons.

Petrovic will step down from her position effective June 1, 2022, but will continue to serve on the company’s board. She will also serve as an advisor to the company through May 2023 to support the leadership transition to Jim Hollingshead, who will succeed Petrovic effective June 1.

Hollingshead has served as an independent member of Insulet’s board of directors since 2019 and currently serves as president of sleep and respiratory care at ResMed.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet posts Street-beating Q1 as Omnipod 5 rollout is ‘progressing very well’

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]Insulet (Nasdaq:PODD) shares were down after hours despite first-quarter results that topped the consensus forecast.

The Acton, Massachusetts-based automated insulin technology developer posted profits of $27.8 million, or 40¢ per share, on sales of $295.4 million for the three months ended March 31, 2022, for a big bottom-line gain from breakeven this time a year ago on sales growth of 17.1%.

Insulet, the maker of the Omnipod 5 automated insulin delivery system, which garnered FDA clearance during the quarter, saw its EPS come in 17¢ ahead of projections on Wall Street, where analysts were looking for sales of $288.2 million.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022

All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week.

From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings.

Here are five of the biggest stories to come out of ATTD 2022:

 

Dexcom’s G7 is accurate in pediatric T1D patients

Dexcom (Nasdaq:DXCM) published new data highlighting the accuracy of the next-generation G7 continuous glucose monitor in children.

The study, published in the Journal of Diabetes and Scientific Technology, evaluated the G7 CGM in children and adolescents with type 1 diabetes. G7, which last month won CE mark approval, remains under FDA 510(k) review.

 

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0